Guangdong Hybribio Biotech Co Ltd Total Liabilities
Guangdong Hybribio Biotech Co Ltd total liabilities. Based on the latest financial reports, Guangdong Hybribio Biotech Co Ltd (300639) has total liabilities worth CN¥475.29 Million CNY (≈ $69.55 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Guangdong Hybribio Biotech Co Ltd (300639) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Guangdong Hybribio Biotech Co Ltd (2012–2025)
Total liabilities of Guangdong Hybribio Biotech Co Ltd from 2012 to 2025. This chart illustrates how Guangdong Hybribio Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Guangdong Hybribio Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guangdong Hybribio Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AB Sagax (publ)
ST:SAGA-D
|
Sweden | Skr49.48 Billion |
|
Puyang Refractories Group Co Ltd
SHE:002225
|
China | CN¥4.98 Billion |
|
Optotech Corp
TW:2340
|
Taiwan | NT$7.48 Billion |
|
ATCO Ltd.
TO:ACO-Y
|
Canada | CA$18.88 Billion |
|
Invengo Information Technology Co Ltd
SHE:002161
|
China | CN¥1.13 Billion |
|
Olympic Steel Inc
NASDAQ:ZEUS
|
USA | $510.93 Million |
|
Yinchuan Xinhua Commercial Group Co Ltd
SHG:600785
|
China | CN¥5.78 Billion |
|
San Bian Science & Technology Co Ltd
SHE:002112
|
China | CN¥1.43 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Guangdong Hybribio Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Guangdong Hybribio Biotech Co Ltd.
Liquidity & Leverage Metrics
Guangdong Hybribio Biotech Co Ltd Total Liabilities Ratios Explained
Guangdong Hybribio Biotech Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guangdong Hybribio Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guangdong Hybribio Biotech Co Ltd (2012–2025)
The table below shows the annual total liabilities of Guangdong Hybribio Biotech Co Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥485.86 Million ≈ $71.10 Million |
-15.71% |
| 2024-12-31 | CN¥576.44 Million ≈ $84.35 Million |
-8.07% |
| 2023-12-31 | CN¥627.05 Million ≈ $91.76 Million |
-58.31% |
| 2022-12-31 | CN¥1.50 Billion ≈ $220.12 Million |
+98.88% |
| 2021-12-31 | CN¥756.37 Million ≈ $110.68 Million |
+134.40% |
| 2020-12-31 | CN¥322.69 Million ≈ $47.22 Million |
+187.27% |
| 2019-12-31 | CN¥112.33 Million ≈ $16.44 Million |
+3.84% |
| 2018-12-31 | CN¥108.17 Million ≈ $15.83 Million |
+9.55% |
| 2017-12-31 | CN¥98.74 Million ≈ $14.45 Million |
+27.43% |
| 2016-12-31 | CN¥77.49 Million ≈ $11.34 Million |
-3.28% |
| 2015-12-31 | CN¥80.11 Million ≈ $11.72 Million |
+95.11% |
| 2014-12-31 | CN¥41.06 Million ≈ $6.01 Million |
-48.44% |
| 2013-12-31 | CN¥79.64 Million ≈ $11.65 Million |
+104.41% |
| 2012-12-31 | CN¥38.96 Million ≈ $5.70 Million |
-- |
About Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-tim… Read more